Jamax-S

Alendronate sodium trihydrate, the active ingredient in Jamax‑S, is a bisphosphonate presented as an oral dosage form for oral use. It treats osteoporosis and related bone disorders in adults.

GNH USA supplies Jamax‑S as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Jamax‑S (alendronate sodium trihydrate) is used in conditions involving increased bone resorption.

- Osteoporosis: reduces the risk of vertebral and hip fractures by inhibiting bone loss. - Paget's disease of bone: normalizes abnormal bone remodeling and alleviates bone pain. - Glucocorticoid‑induced osteoporosis: prevents bone loss associated with long‑term steroid therapy.

Common side effects are generally mild and related to gastrointestinal irritation or transient musculoskeletal discomfort.

Common Side Effects: - Abdominal pain - Dyspepsia - Nausea - Constipation - Musculoskeletal pain - Headache

Serious or Rare Side Effects: - Esophageal ulceration or erosion - Osteonecrosis of the jaw - Atypical femur fracture - Severe hypersensitivity reactions - Acute phase reaction (fever, myalgia) - Renal impairment

Before initiating therapy, clinicians should evaluate renal function, gastrointestinal health, and concomitant medications.

- Assess renal function: avoid use in severe renal impairment. - Ensure upright posture: remain upright for at least 30 minutes after ingestion. - Separate from calcium, antacids, or multivitamins: take at least 30 minutes before or after such agents. - Review history of esophageal disorders: contraindicated in patients with active esophageal disease. - Monitor for jaw pain or exposed bone: advise dental evaluation before starting. - Store at room temperature: keep in the original pack, protect from moisture.

Alendronate may interact with several medicines, requiring avoidance or close monitoring.

Major Interactions (Avoid): - Antacids or supplements containing calcium, magnesium, aluminum, or iron within 30 minutes of dosing. - Concomitant use of other bisphosphonates or high‑dose vitamin D preparations. - Co‑administration with nephrotoxic agents in patients with impaired renal function.

Moderate Interactions (Monitor Closely): - NSAIDs or corticosteroids (increase risk of gastrointestinal irritation). - Warfarin (potential alteration of INR; monitor coagulation). - Proton pump inhibitors (may reduce oral absorption; observe therapeutic response).